Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
暂无分享，去创建一个
I. Nagtegaal | B. Ylstra | C. Punt | L. Vermeulen | D. Sommeijer | M. Koopman | C. V. van Noesel | R. J. Reinten | E. van Dijk | Tom van den Bosch | Lisanne E. Nijman | L. Mol | Tim R. de Back | S. ten Hoorn